In conclusion, our study indicated that this approach achieved safe and efficient intracellular delivery of antibodies and degraded BCR/ABL oncoprotein via the Trim-Away pathway, which provides a promising therapeutic strategy for CML patients, particularly those with TKI resistance. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.